Physician profile
Erin Cunningham
NPI 1730519414
$1,091.20
in general payments reported to CMS, 2019-2025
25 companies · $459 in 2025
The $459 reported for 2025 was more than what 75% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.50 · 2022: $256 · 2023: $257 · 2024: $79.66 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $182.75 | 2022-2025 | |
| Genzyme Corporation | $149.76 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $130.11 | 2022-2025 | |
| Janssen Biotech, INC. | $57.45 | 2022-2025 | Imbruvica, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $48.86 | 2022-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $47.30 | 2022 | |
| Pharmacosmos Therapeutics INC. | $46.47 | 2024-2025 | Monoferric |
| Stemline Therapeutics INC. | $39.77 | 2024-2025 | Orserdu |
| Amgen INC. | $39.74 | 2022-2023 | Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $38.50 | 2021 | |
| Genentech USA, INC. | $35.89 | 2022-2023 | Venclexta |
| Merck Sharp & Dohme LLC | $33.11 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $31.89 | 2023 | Trodelvy |
| Array Biopharma INC | $26.78 | 2025 | Braftovi, Tukysa, Mektovi |
| Sun Pharmaceutical Industries INC. | $22.46 | 2023 | Yonsa, Odomzo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.15 | 2024 | |
| Daiichi Sankyo INC. | $18.57 | 2025 | Datroway |
| Glaxosmithkline, LLC. | $18.56 | 2025 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $17.24 | 2023 | |
| Rigel Pharmaceuticals, INC. | $15.94 | 2023 | Tavalisse, Rezlidhia |
| Takeda Pharmaceuticals U.S.A., INC. | $15.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.95 | 2022 | |
| Aveo Pharmaceuticals, INC. | $13.69 | 2022 | |
| Seagen INC. | $12.68 | 2022 | |
| Lilly USA, LLC | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.